396OA multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer. (25th November 2018) - Han, B; Li, K; Chu, T; Bi, M; Zhang, H; Yu, Y; Shi, J; Zhang, X; Chen, Z; Han, C; Bai, T